Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02483585 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 577
- Enrollment target
NCT02483585 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 577 participants.
The verdict
NCT02483585, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 577 participants
- Enrollment target
Study Summary
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
Interventions
- DRUG Placebo
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 577 participants |
| Start Date | 2015-07-20 |
| Est. Completion | 2017-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02483585
The ClinicalTrials.gov registry entry for NCT02483585 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 577 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02483585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02483585 about?
NCT02483585 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention". To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
What is the current status of trial NCT02483585?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 577 participants. The study started on 2015-07-20. Estimated completion is 2017-03-20.
What interventions are being tested in trial NCT02483585?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT02483585?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.